scholarly journals Early complete response of primary bone marrow B‐cell lymphoma treated with rituximab‐based CHOP therapy, assessed by flow cytometry and immunogloblin heavy chain rearrangement

2021 ◽  
Vol 9 (8) ◽  
Author(s):  
Yoshimi Nabe ◽  
Shohei Kikuchi ◽  
Yusuke Kamihara ◽  
Akinori Wada ◽  
Jun Murakami ◽  
...  
Author(s):  
Yoshimi Nabe ◽  
Shohei Kikuchi ◽  
Yusuke Kamihara ◽  
Akinori Wada ◽  
Jun Muarakami ◽  
...  

Primary bone marrow B-cell lymphoma (PBML) is a special subtype of DLBCL which can be repeatedly sampled and evaluated by FCM and IGH rearrangement. Evaluation of early response by FCM and IGH assessments in the midpoint of treatment could be valuable for predicting treatment outcome.


2015 ◽  
Vol 4 (4) ◽  
pp. 242-245
Author(s):  
Monika Gupta ◽  
Shalini Shah ◽  
Nisha Marwah ◽  
Megha Kathuria ◽  
Sonia Chhabra ◽  
...  

2018 ◽  
Vol 2018 ◽  
pp. 1-5 ◽  
Author(s):  
Jin Sae Yoo ◽  
Juwon Kim ◽  
Hyeong Ju Kwon ◽  
Jung Soo Lim

Purpose. We report a rare case of severe hypercalcemia that was ultimately diagnosed as primary bone marrow diffuse large B-cell lymphoma (BCL). Case Report. A 74-year-old male patient visited our hospital complaining of tenderness and swelling of the left knee caused by supracondylar fracture of the left distal femur. His initial blood tests showed a serum calcium level of 13.9 mg/dL, inorganic phosphorus of 4.34 mg/dL, and a serum creatinine level of 1.54 mg/dL. A serum assay of intact parathyroid hormone showed 5.24 pg/mL, and the patient’s serum 25(OH)D level was 22.33 ng/mL. To exclude malignancy, we performed imaging studies, including abdomen or chest computed tomography and positron emission tomography-computed tomography; however, no suspicious lesion was found, although the serum PTH-related peptide level was elevated at 4.0 pmol/L. A bone marrow biopsy was performed to identify any hidden hematologic malignancy. As a result, the pathology of bone marrow confirmed the presence of atypical lymphocytes that stained positive for the CD20 marker, which is consistent with BCL involving the bone marrow. Conclusion. This case highlights the importance of pursuing a thorough workup for rare underlying causes of hypercalcemia when parathyroid-related etiologies can be excluded.


2010 ◽  
Vol 90 (7) ◽  
pp. 791-796 ◽  
Author(s):  
Hung Chang ◽  
Yu-Shin Hung ◽  
Tung-Liang Lin ◽  
Po-Nan Wang ◽  
Ming-Chung Kuo ◽  
...  

2011 ◽  
Vol 204 (9) ◽  
pp. 501-506 ◽  
Author(s):  
Katsuya Yamamoto ◽  
Hiroshi Matsuoka ◽  
Kimikazu Yakushijin ◽  
Yohei Funakoshi ◽  
Atsuo Okamura ◽  
...  

2021 ◽  
Vol 2021 ◽  
pp. 1-3
Author(s):  
Mark G. Evans ◽  
Sherif A. Rezk ◽  
Lauren C. Pinter-Brown ◽  
Xiaohui Zhao

Primary bone marrow diffuse large B-cell lymphoma is an exceedingly rare form of non-Hodgkin lymphoma. It may demonstrate a leukemic presentation, and a proportion of cases have CD5 expression. The prognostic implications of this CD5-positivity remain unknown. Here, we present a 78-year-old man who presented with circulating peripheral blood lymphoma cells and a hypercellular marrow involved by diffuse large B-cell lymphoma, germinal center B-cell subtype. The patient responded favorably to six cycles of etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab (EPOCH-R) and intrathecal methotrexate. He unfortunately relapsed in several enlarged inguinal lymph nodes and succumbed to the lymphoma approximately one year after diagnosis, demonstrating the particularly aggressive clinical course of his disease.


2016 ◽  
Vol 11 (5) ◽  
pp. 3428-3432 ◽  
Author(s):  
SAISAI REN ◽  
YANLING TAO ◽  
LU JIA ◽  
PANPAN CHENG ◽  
JILEI ZHANG ◽  
...  

2016 ◽  
Vol 23 (4) ◽  
pp. 256
Author(s):  
In-Young Kim ◽  
Dam Kim ◽  
Byeong Bae Park ◽  
Woong-Soo Lee ◽  
Ji-Young Choi ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document